Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents

Pharmazie

Volumn 61, Issue 3, 2006, Pages 179-182

  Petroianu, G ^a   Arafat, K ^a   Sasse, B C ^b   Stark, Holger ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE METHYLTRANSFERASE; TACRINE;

ALZHEIMER DISEASE; ARTICLE; COGNITION; COLORIMETRY; DRUG EFFECT; DRUG INHIBITION; ENZYME INHIBITION; HUMAN; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; COGNITION; HISTAMINE ANTAGONISTS; HISTAMINE N-METHYLTRANSFERASE; HUMANS; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33645361406     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105-2115.
2. 3 receptor ligands with combined inhibitory histamine N-methyltransferase activity. J Med Chem 45: 1128-1141.
3. Ballard CG (2002) Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 47: 64-70.
4. Crismon ML (1994) Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 28: 744-751.
5. Cumming P, Vincent SR (1992) Inhibition of histamine-N-methyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydroacridine (tacrine) and by β-carbolines. Biochem Pharmacol 44: 989-992.
6. Darvesh S, Hopkins DH, Geula C (2003) Neurobiology of butyrylcholin-esterase. Nat Rev Neurosci 4: 131-138.
7. Dorronsoro I, Castro A, Martinez A (2003) Peripheral and dual binding site inhibitors of acteylcholinesterase as neurodegenerative disease-modifying agents. Exp Opin Ther Patents 13: 1725-1732.
8. Ellmann CL, Courtney D, Andres V, Featherstone R (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
9. Giacobini E (2001) Selective inhibitors of butyrylcholinesterase: a valid alternative for the therapy of Alzheimer's disease? Drugs Aging 18: 891-898.
10. Giacobine E (2003) Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 28: 515-522.
11. Farlow MR (2002) Do cholinesterase inhibitors slow progression of Alzheimer's disease? Int J Clin Pract Suppl 127: 37-44.
12. 3 receptor affinities. Bioorg Med Chem 11: 2163-2174.
13. 3-receptor antagonists. Eur J Pharm Sci 13: 249-259.
14. Morisset S, Traiffort E, Schwartz JC (1996) Inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity. Eur J Pharmacol 315: 1-2.
15. 4 receptor ligands. Expert Opin Ther Patents 13: 851-865.
16. Stark H (2004) Turning from monogamy to strategic promiscuity. Drug Disc Today 9: 736-737.
17. Soreq H, Seidmann S (2001) Acetylcholinesterase - new roles for an old actor. Nat Rev Neurosci 2: 294-302.
18. Van Kampen EJ, Zijlstra WG (1961) Standardization of hemoglobinometry II. The hemoglobincyanide method. Clin Chim Acta 6: 538-544.
19. 3 receptor antagonists for the treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 103: 1-20.
20. Worek F, Mast U, Kiderlen D, Diepold C, Eyer P (1999) Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 288: 73-90.